

# Effect of Bisphosphonates or Teriparatide on Mechanical Complications after Posterior Instrumented Fusion for Osteoporotic Vertebral Fracture: A Multi-center Retrospective Study

**Atsuyuki Kawabata**

Tokyo Medical and Dental University

**Toshitaka Yoshii** (✉ [yoshii.orth@tmd.ac.jp](mailto:yoshii.orth@tmd.ac.jp))

Tokyo Medical and Dental University

**Takashi Hirai**

Tokyo Medical and Dental University

**Shuta Ushio**

Tokyo Medical and Dental University

**Takashi Kaito**

Osaka University

**Tomoya Yamashita**

Osaka University

**Hiroyasu Fujiwara**

Osaka University

**Yukitaka Nagamoto**

Osaka University

**Yuji Matsuoka**

Tokyo Medical University

**Hidekazu Suzuki**

Tokyo Medical University

**Hirosuke Nishimura**

Tokyo Medical University

**Hidetomi Terai**

Osaka City University

**Koji Tamai**

Osaka City University

**Atsushi Tagami**

Nagasaki University

**Syuta Yamada**

Nagasaki University

**Shinji Adachi**

Nagasaki University

**Kei Watanabe**

Niigata University Medical and Dental General Hospital

**Keiichi Katsumi**

Niigata University Medical and Dental General Hospital

**Masayuki Ohashi**

Niigata University Medical and Dental General Hospital

**Yohei Shibuya**

Niigata University Medical and Dental General Hospital

**Katsumi Harimaya**

Kyushu University

**Kenichi Kawaguchi**

Kyushu University

**Nobuhiko Yokoyama**

Kyushu University

**Hidekazu Oishi**

Kyushu University

**Toshiro Doi**

Kyushu University

**Atsushi Kimura**

Jichi Medical University

**Hirokazu Inoue**

Jichi Medical Hospital

**Gen Inoue**

Kitasato University

**Masayuki Miyagi**

Kitasato University

**Wataru Saito**

Kitasato University

**Atsushi Nakano**

Osaka Medical College

**Daisuke Sakai**

Tokai University

**Tadashi Nukaga**

Tokai University

**Shota Ikegami**

Shinshu University

**Masayuki Shimizu**

Shinshu University

**Toshimasa Futatsugi**

Shinshu University

**Seiji Ohtori**

Chiba University

**Takeo Furuya**

Chiba University

**Sumihisa Orita**

Chiba University

**Shiro Imagama**

Nagoya University

**Kei Ando**

Nagoya University

**Kazuyoshi Kobayashi**

Nagoya University

**Katsuhito Kiyasu**

Kochi University

**Hideki Murakami**

Kanazawa University

**Katsuhito Yoshioka**

Kanazawa University

**Shoji Seki**

Toyama University

**Michio Hongo**

Akita University

**Kenichiro Kakutani**

Kobe University

**Takashi Yurube**

Kobe University

**Yasuchika Aoki**

Eastern Chiba Medical Center

**Masashi Oshima**

Nihon University Itabashi Hospital

**Masahiko Takahata**

Hokkaido University

**Akira Iwata**

Hokkaido University

**Hirooki Endo**

Iwate Medical University

**Tetsuya Abe**

University of Tsukuba

**Toshinori Tsukanishi**

University of Tsukuba

**Kazuyoshi Nakanishi**

Hiroshima University

**Kota Watanabe**

Keio University School of Medicine

**Tomohiro Hikata**

Keio University School of Medicine

**Satoshi Suzuki**

Keio University School of Medicine

**Norihiro Isogai**

Keio University School of Medicine

**Eijiro Okada**

Keio University School of Medicine

**Haruki Funao**

Keio University School of Medicine

**Seiji Ueda**

Keio University School of Medicine

**Yuta Shiono**

Keio University School of Medicine

**Kenya Nojiri**

Keio University School of Medicine

**Naobumi Hosogane**

National Defence Medical College

**Ken Ishii**

Internatinal University of Health and Welfare School of Medicine

---

## Research article

**Keywords:** bisphosphonates, teriparatide, osteoporotic vertebral fractures, surgery, primary osteoporosis, glucocorticoid-induced osteoporosis

**Posted Date:** February 28th, 2020

**DOI:** <https://doi.org/10.21203/rs.3.rs-15464/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

**Version of Record:** A version of this preprint was published on July 1st, 2020. See the published version at <https://doi.org/10.1186/s12891-020-03452-6>.

# Abstract

**Background:** The optimal treatment of osteoporosis after reconstruction surgery for osteoporotic vertebral fractures (OVF) remains unclear. In this multicentre retrospective study, we investigated the effects of typically used agents for osteoporosis, namely, bisphosphonates (BP) and teriparatide (TP), on surgical results in patients with osteoporotic vertebral fractures.

**Methods:** Retrospectively registered data were collected from 27 universities and affiliated hospitals in Japan. We compared the effects of BP vs TP on postoperative mechanical complication rates, implant-related reoperation rates, and clinical outcomes in patients who underwent posterior instrumented fusion for OVF and had been followed up at least for 2 years. Data were analysed according to whether the osteoporosis was primary or glucocorticoid-induced.

**Results:** A total of 165 patients who underwent posterior instrumented fusion for OVF were included. The overall mechanical complication rate was significantly lower in the TP group than in the BP group (BP vs TP: 73.0% vs. 55.7%,  $p = 0.018$ ). The screw backout rate was significantly lower and the rates of new vertebral fractures and pseudoarthrosis tended to be lower in the TP group than in the BP group. However, there were no significant differences in lumbar functional scores and visual analogue scale pain scores or in implant-related reoperation rates between the two groups. The incidence of pseudoarthrosis was significantly higher in patients with glucocorticoid-induced osteoporosis (GIOP) than in those with primary osteoporosis; however, the pseudoarthrosis rate was reduced by using TP. The use of TP also tended to reduce the overall mechanical complication rate in both primary osteoporosis and GIOP.

**Conclusions:** The overall mechanical complication rate was lower in patients who received TP than in those who received a BP postoperatively, regardless of type of osteoporosis. The incidence of pseudoarthrosis was significantly higher in patients with GIOP, but the use of TP reduced the rate of pseudoarthrosis in GIOP patients.

## Background

Osteoporotic vertebral fractures (OVFs) are the most common type of fragility fracture and are sustained by 25% of individuals in their early 70 s and 43% of those aged over 80 years [1]. OVFs cause low back pain, which significantly impacts quality of life. Many cases can be cured by conservative treatment using a brace [2], but surgery may be performed when early mobilization is desired, conservative treatment fails, or the posterior segment of the vertebra is destroyed, accompanied by neurological deficit [3]. Surgery is also an effective option for preventing progressive kyphosis after fracture. The recent advent of the percutaneous pedicle screw has made it possible to perform minimally invasive surgery in these patients [4]. However, because of the bone fragility in the background, surgically treated patients may experience screw loosening or pseudoarthrosis and revision surgery may be required [5].

Bisphosphonates (BP) and teriparatide (TP) are widely used for the prevention of osteoporosis. BP are the first-line agents for osteoporosis and have been shown to prevent fragile fractures by inhibiting

osteoclasts [6]. TP is a recombinant form of human parathyroid hormone and is the first osteogenic agent to enter clinical use. Improvements in lumbar bone mineral density (BMD) of 4.54–7.48% have been reported for BP, whereas 6.4% improvement of BMD was reported after 2 years of administration of TP [7]. However, because TP is expensive and its allowed duration of administration is limited, the use of TP is problematic in terms of timing [8]. In contrast, several studies have reported osteonecrosis of the jaw or atypical femoral fracture as adverse effects of BP [9–11].

Previous studies have demonstrated the superiority of TP over BP in patients who have undergone conservative treatment for OVF according to bone union rates [12–14]. Other studies have shown the positive effects of TP on bony fusion after spinal fusion or correction surgery [15–20]. TP has bone anabolic ability and can reduce the chance of screw loosening, and so the use of BP may effectively enhance spinal fusion and reduce implant failure and/ or subsequent vertebral fracture in comparison with surgery [16, 19, 20]. However, there is limited literature on the relationship between administration of these agents and mechanical complications after posterior fusion surgery for OVF. Furthermore, few studies have investigated the effects of TP and BP in patients with glucocorticoid-induced osteoporosis (GIOP). Therefore, optimal treatment of osteoporosis after reconstruction surgery for OVF remains unclear. The aim of this nationwide multicentre retrospective study was to investigate the effects of these osteoporosis medications on surgical outcomes, specifically mechanical complications and reoperation rates in patients with primary OVF or GIOP.

## Methods

We retrospectively reviewed all patients who were treated surgically with instrumentation for OVF between 2005 and 2014 at 27 universities and affiliated hospitals that contribute data to the multicentre Japan Association of Spine Surgeons with Ambition (JASA) database. Institutional review board approval was obtained at each site for patient enrollment and the data collection protocols. The need for informed consent was waived by the ethics committees because this retrospective cohort study involved existing data and records at the time of investigation, and did not retain personal identifiers in the collected information. The inclusion criteria were treatment with a BP or TP after surgery, follow-up for at least 2 years, and surgery with instrumented posterior spinal fusion. TP was continued for 2 years and then switched to a BP. Patients who received other osteoporosis medications, such as denosumab or a selective oestrogen receptor modulator, were excluded. The aetiology was primary osteoporosis or GIOP. Other secondary osteoporosis was excluded. The operative procedure in the database was divided into anterior spinal fusion, posterior spinal fusion alone with or without vertebroplasty, and anterior and posterior three-column osteotomy. Patients who underwent posterior spinal fusion fixation for less than five levels were included in this study. Demographic data including age, sex, body mass index, BMD (expressed as the young adult mean [YAM] score), and preoperative and postoperative use of osteoporosis agents were collected.

As previously described, postoperative mechanical complications were defined as screw loosening, screw backout, screw breakage, rod breakage, and an adjacent vertebral fracture with or without revision surgery

[21]. Clinical outcomes were evaluated using the Japanese Orthopaedic Association (JOA) scoring system for lumbar function [22]. The visual analogue scale (VAS) score was used to grade the severity of low back pain and pain or numbness in the lower extremities (0, no symptoms; 10, worst symptoms imaginable). The patients were divided into those who received BP and those who received TP, postoperatively. We compared the patient's demographics and surgical outcomes, as well as postoperative complications between the BP and TP group. Further, we compared the effect of BP and TP for patients with primary osteoporosis and GIOP.

The t-test or chi-squared test was used to compare the two groups. The averages of continuous variables were compared between the groups using t-tests and the proportions of categorical variables were compared using chi-square tests. All statistical analyses were performed using IBM SPSS Statistics for Macintosh software version 25.0 (IBM Corp., Armonk, NY). A p-value < 0.05 was considered statistically significant.

## Results

One hundred and sixty-five patients who underwent posterior instrumented fusion during the study period met the inclusion criteria. The mean patient age at the time of surgery was  $75.4 \pm 7.2$  years and 141 patients (85.4%) were female. The mean YAM score was  $73.0 \pm 16.1\%$ . The OVs were caused by primary osteoporosis in 138 patients and by GIOP in 27 patients.

Table 1 shows the patient characteristics according to type of osteoporosis. Mean patient age at the time of surgery was significantly higher in the primary osteoporosis group than in the GIOP group ( $76.0 \pm 7.2$  years vs.  $71.0 \pm 6.1$  years;  $p = 0.001$ ). Significantly more patients in the GIOP group received a osteoporosis medication preoperatively ( $p < 0.001$ ). However, there was no significant between-group difference in sex, body mass index, smoking history, BMD, or number of fixed levels. The preoperative JOA and VAS scores for back pain and leg symptoms were also similar between the two groups.

Table 1. Demographic characteristics and postoperative complications according to whether osteoporosis was primary or glucocorticoid-induced

	<b>Total</b>	<b>Primary</b>	<b>GIOP</b>	<b>p-value</b>
Cases, n	165	138	27	-
Age at time of surgery (years)	75.4 ± 7.2	76.3 ± 7.2	71.0 ± 6.1	0.001
Sex (male)	24 (14.5%)	22 (15.9%)	2 (7.4%)	0.373
BMI	22.4 ± 5.1	22.4 ± 4.5	22.3 ± 6.4	0.939
Smoking history (yes/no)	20 (12.1%)	19 (13.7%)	1 (3.7%)	0.203
BMD (YAM%)	71.0 ± 16.1	70.6±14.5	73.5 ± 16.4	0.485
Preoperative use of osteoporosis medication (yes/no)	75 (45.5%)	53 (38.4%)	22 (81.4%)	<0.001
Fixed level	3.1 ± 0.8	3.1 ± 0.8	3.0 ± 0.9	0.249
Preoperative JOA score	9.6 ± 3.2	9.8 ± 3.3	9.1 ± 3.0	0.202
Preoperative VAS (back pain)	73.6 ± 23.4	73.4 ± 23.1	76.8 ± 23.5	0.453
Preoperative VAS (leg pain or numbness)	55.4 ± 31.6	54.9 ± 31.9	56.8 ± 30.3	0.740

BMD, bone mineral density; BMI, body mass index; GIOP, glucocorticoid-induced osteoporosis; JOA, Japan Orthopaedic Association; OVF, osteoporotic vertebral fracture; VAS, visual analogue scale; YAM, young adult mean.

The demographic characteristics in the BP and TP groups are shown in Table 2. There was no significant difference in age, sex, body mass index, BMD, smoking status, number of previous vertebral fractures, or the preoperative JOA or VAS scores between the two groups.

Preoperative use of osteoporosis medication was significantly more common in the TP group than in the BP group (46.6% vs. 33%,  $p = 0.018$ ). There was no significant difference in the number of fixed levels between the two groups.

Table 2. Preoperative demographic and clinical characteristics according to whether osteoporosis medication was BP or TP

	<b>BP</b>	<b>TP</b>	<b>p-value</b>
Cases, n	104	61	-
Age at surgery, years	75.2 ± 6.8	75.8 ± 8.0	0.64
Sex (male)	15 (14.4%)	9 (14.8%)	0.95
BMI	22.2 ± 4.8	22.7 ± 5.6	0.57
Smoking history	14 (13.5%)	6 (9.8%)	0.62
Previous vertebral fracture	28 (26.9%)	18 (29.5%)	0.72
BMD*, YAM%	72.5 ± 17.7	73.8 ± 13.7	0.68
Preoperative drug use for osteoporosis	39 (37.5%)	36 (59.0%)	0.010
Fixed levels	3.0 ± 0.8	3.2 ± 0.8	0.127
Preoperative JOA score	4.77 ± 3.55	4.05 ± 3.34	0.146
Preoperative VAS (back pain)	71.2 ± 22.9	76.8 ± 23.1	0.101
Preoperative VAS (leg pain or numbness)	53.1 ± 31.6	57.4 ± 32.6	0.380

BMD, bone mineral density; BMI, body mass index; BP, bisphosphonate; JOA, Japanese Orthopaedic Association; OVF, osteoporotic vertebral fracture; TP, teriparatide; VAS, visual analogue scale; YAM, young adult mean.

Table 3 shows the postoperative complications and clinical outcomes in the BP and TP groups. The overall mechanical complication rate was significantly higher in the BP group than in the TP group (73.0% vs. 55.7%,  $p = 0.018$ ). The screw backout rate was significantly lower and the rates of development of new vertebral fractures and pseudoarthrosis tended to be lower in the TP group than in the BP group (screw backout, 1.6% vs. 12.5%; vertebral fracture, 32.8% vs. 45.2%; pseudoarthrosis, 1.6% vs. 8.7%). There were no significant differences in the rates of revision surgery or other complications, such as screw loosening and rod fracture, between the groups. Furthermore, there were no significant differences in the postoperative JOA and VAS scores or in their rates of improvement.

Table 3. Postoperative complications and clinical outcomes according to whether osteoporosis medication was BP or TP

	<b>BP</b>	<b>TP</b>	<b>p-value</b>
Cases, n	104	61	-
Mechanical complications	76 (73.1%)	34 (55.7%)	0.018
New vertebral fracture	47 (45.2%)	20 (32.8%)	0.080
Screw complications	42 (40.4%)	19 (31.1%)	0.248
Screw loosening (yes/no)	29 (27.9%)	18 (29.5%)	0.859
Screw backout	13 (12.5%)	1 (1.6%)	0.018
Rod fracture	0	0	-
Pseudoarthrosis	9 (8.7%)	1 (1.6%)	0.062
Revision due to mechanical complications	10 (9.6%)	9 (14.8%)	0.325
Postoperative JOA	9.9 ± 3.2	9.6 ± 3.3	0.484
Recovery rate of JOA	48.8 ± 29.1	52.4 ± 23.8	0.303
Final VAS (back pain)	30.6 ± 23.3	31.8 ± 24.9	0.712
Change in VAS (back pain)	40.5 ± 30.9	44.2 ± 30.7	0.372
Final VAS (leg pain or numbness)	18.8 ± 21.2	22.8 ± 26.7	0.230
Change in VAS (leg pain or numbness)	33.4 ± 28.9	33.1 ± 31.7	0.922

BP, bisphosphonate; JOA, Japanese Orthopaedic Association; TP, teriparatide; VAS, visual analogue scale.

Table 4 shows postoperative complications and clinical outcomes compared between the patients with primary osteoporosis and those with GIOP. The rate of pseudoarthrosis was significantly higher in patients with GIOP than in those with primary osteoporosis (14.8% vs. 4.3%, p=0.027). Other complications were not significantly different between the two groups. There were no significant differences in postoperative JOA and VAS scores or the recovery rates.

Table 4. Postoperative complications and clinical outcomes according to whether osteoporosis was primary or glucocorticoid-induced

	Primary osteoporosis	GIOP	p-value
Cases, n	138	27	-
Mechanical complications	93 (67.4%)	17 (63.0%)	0.902
New vertebral fracture	59 (42.8%)	8 (29.6%)	0.239
Screw complications	54 (39.1%)	7 (25.9%)	0.329
Screw loosening	42 (30.4%)	5 (18.5%)	0.302
Screw backout	12 (8.7%)	2 (7.4%)	0.992
Rod fracture	0	0	-
Pseudoarthrosis	6 (4.3%)	4 (14.8%)	0.027
Revision due to mechanical complications	17 (12.3%)	2 (7.4%)	0.246
Postoperative JOA	9.8 ± 3.5	8.8 ± 3.0	0.171
Recovery rate of JOA	50.6 ± 27.6	46.1 ± 20.1	0.360
Final VAS (back pain)	30.2 ± 23.3	32.1 ± 20.6	0.689
Change in VAS (back pain)	41.3 ± 30.5	39.4 ± 29.8	0.785
Final VAS (leg pain or numbness)	18.8 ± 21.8	22.3 ± 23.4	0.509
Change in VAS (leg pain or numbness)	35.1 ± 29.3	34.8 ± 23.3	0.962

GIOP, glucocorticoid-induced osteoporosis; JOA, Japanese Orthopaedic Association; TP, teriparatide; VAS, visual analogue scale.

Table 5 shows the postoperative complications and clinical outcomes in the BP and TP groups according to whether the cause of OVF was primary osteoporosis or GIOP. The overall mechanical complication, screw backout, and pseudoarthrosis rates tended to be reduced by the use of TP compared to the use of BP in patients with primary osteoporosis (overall mechanical complications, 72.0% vs. 57.8%,  $p = 0.070$ ; screw backout, 11.8% vs. 2.2%,  $p = 0.060$ ; pseudoarthrosis, 6.5% vs. 0%,  $p = 0.081$ ). Even in patients with GIOP, the rates of

these complications were smaller by using TP (overall complications, 81.8% vs. 50%,  $p = 0.093$ ; screw backout, 18.2% vs. 0%  $p = 0.076$ ; pseudoarthrosis, 27.3% vs. 6.3%,  $p = 0.13$ ). The screw loosening and revision surgery rates were not different between the BP and TP groups in both types of osteoporosis. There were no significant differences in the postoperative JOA and VAS scores or their recovery rates.

Table 5. Postoperative complications and clinical outcomes in the BP and TP groups according to whether the cause of OVF was primary osteoporosis or GIOP

	Primary osteoporosis			GIOP		
	BP	TP	p-value	BP	TP	p-value
Cases, n	93	45	-	11	16	-
Mechanical complications	67 (72.0%)	26 (57.8%)	0.07	9 (81.8%)	8 (50%)	0.093
New vertebral fracture	42 (45.2%)	17 (37.8%)	0.41	5 (45.5%)	3 (18.8%)	0.14
Screw complications	39 (41.9%)	15 (33.3%)	0.33	3 (27.3%)	4 (25.0%)	0.90
Screw loosening	28 (30.1%)	14 (31.1%)	0.90	1 (9.1%)	4 (25.0%)	0.30
Screw backout	11 (11.8%)	1 (2.2%)	0.06	2 (18.2%)	0	0.076
Rod fracture	0	0	-	0	0	-
Pseudoarthrosis	6 (6.5%)	0	0.08	3 (27.3%)	1 (6.3%)	0.13
Revision due to mechanical complications	10 (10.8%)	7 (15.6%)	0.42	0	2 (12.5%)	0.50
Postoperative JOA score	9.9 ± 3.3	9.7 ± 3.3	0.58	9.3 ± 3.2	8.3 ± 3.0	0.49
JOA score recovery rate	49.2 ± 30.1	52.8 ± 23.3	0.36	48.0 ± 19.8	44.7 ± 26.3	0.69
Final VAS (back pain)	30.9 ± 23.7	32.2 ± 25.7	0.73	27.2 ± 20.1	36.2 ± 20.3	0.30
Change in VAS (back pain)	40.5 ± 30.9	43.5 ± 30.7	0.53	40.3 ± 26.7	38.7 ± 33.6	0.90
Final VAS (leg pain or	18.9 ±	18.4 ±	0.90	15.0 ±	28.9 ±	0.15

numbness)	21.4	22.7		14.7	28.2	
Change in VAS (leg pain or	34.7 ±	35.7 ±	0.88	29.2 ±	39.9 ±	0.28
numbness)	28.9	32.0		20.9	25.1	

BP, bisphosphonate; TP, teriparatide; OVF, osteoporotic vertebral fracture; GIOP, glucocorticoid-induced osteoporosis; JOA, Japanese Orthopaedic Association; VAS, visual analogue scale.

## Discussion

Previous studies have demonstrated that TP has a higher union rate in patients with OVF who were treated conservatively compared with those treated with BP [12–14]. However, little is known about the effect of these agents in patients with surgically treated OVF. Furthermore, there has been no comparison of the surgical outcomes between patients with primary osteoporosis and those with GIOP. In this study, we compared the surgical complications and clinical outcomes between patients with primary osteoporosis and GIOP. We then compared the effects of postoperative administration of teriparatide on surgical complication and reoperation rates with those of BP in patients with primary osteoporosis and in patients with GIOP.

The demographic data showed that patients with GIOP were younger at the time of surgery than those with primary osteoporosis. This finding indicates that vertebral fractures can occur at a relatively younger age in patients with GIOP. Consistent with this result is a report describing vertebral fractures occurring at a relatively young age in patients with GIOP, and the severity of the collapse was unexpectedly disproportionate to the age of the patients [23]. In our study, patients with GIOP had a relatively higher BMD than those with primary osteoporosis. A previous study also reported that patients on glucocorticoids experienced fractures at a higher BMD than the general population (i.e., the “BMD and bone fragility paradox”) [24]. The effect of glucocorticoids on bone is mediated by multiple pathophysiologic mechanisms resulting in an inhibition of bone formation and an increase in bone resorption. Glucocorticoids also impair the function of osteocytes and thus lead to impaired bone architecture [23] [24]. Saito et al. reported that deterioration of bone material properties advances with glucocorticoid use and the resulting alterations in bone quality are not captured by BMD [25]. Thus, dual-energy X-ray absorptiometry may underestimate the risk of fracture, which is estimated to be high even though the value of BMD is relatively high in patients treated with glucocorticoids.

In our study, the overall mechanical complication and screw backout rates were significantly lower and the new vertebral fracture and pseudoarthrosis rates tended to be lower in the TP group. Previous studies suggested that rates of screw loosening and fusion are significantly lower in patients with osteoporosis who have undergone posterolateral fusion with a local bone graft or posterior interbody fusion and received TP than in their counterparts treated with BP [20]. In a prospective comparison of these

osteoporotic medications in 58 surgically treated patients with adult spinal deformity, Seki et al. found that adjacent vertebral fracture, implant failure, and fusion failure rates were significantly lower in their TP group than in their BP group [15]. TP has a bone anabolic effect and has effects on both bone fusion promotion and screw loosening. It may also reduce the risk of new fractures in OVF patients by 38%. Therefore, even in surgically treated case of OVF, it is considered to be useful for reducing mechanical complications and pseudoarthrosis.

In the comparison of primary and steroid-induced osteoporosis, our study showed that the rate of pseudoarthrosis was significantly higher in the patients with GIOP than in those with primary osteoporosis. Previous studies have reported that systemic corticosteroid therapy interfered with bony healing in a rabbit model, with a 60% lower union rate in the steroid group [26, 27]. Consistent with these studies, our results suggested that glucocorticoid use hindered bony union of fracture sites in patients who underwent posterior spinal fusion. However, our study also demonstrated a favourable effect of TP compared with BP for prevention of pseudoarthrosis in patients with GIOP. Thus, administration of TP is a viable option to improve the rate of bony healing especially for patients with GIOP.

We found that TP tended to reduce mechanical complications and pseudoarthrosis regardless of whether osteoporosis was primary or glucocorticoid-induced when compared with BP. Furthermore, the effect of TP on prevention of new vertebral fractures was stronger in our patients with GIOP than in those with primary osteoporosis. Saag et al. have demonstrated that TP is an effective treatment for GIOP and that it was superior to alendronate for prevention of vertebral fractures at 36 months (1.7% vs. 7.7%) [28]. In accordance with the previous study, we found that TP had a positive effect on the mechanical complication rate. However, there has been a suggestion that the effect of TP is attenuated when the glucocorticoid dosage is higher than 15 mg/day [24]. Only four patients in our study were on glucocorticoid doses higher than 15 mg/day, thus a further study is needed to clarify the association between high-dose glucocorticoids and the effect of TP.

Previous studies have found better quality of life and VAS scores for back pain in patients treated with TP than in those treated with BP. In a crossover study by Jakob et al, postmenopausal women with osteoporosis who switched from a BP to TP reported better health-related quality of life and had improved VAS scores for back pain [12]. In our study, despite the positive effect of TP on mechanical complications, postoperative JOA and VAS scores for back pain were not significantly different between the TP and BP group. A possible explanation for this result is that posterior fusion itself results in marked improvement in the VAS score and quality of life. Therefore, symptoms in patients who received BP were also sufficiently improved by surgery, such that the effect of TP may not have been significant. However, the difference in mechanical complication rates between TP and BP may further increase during long term follow-up, which may result in marked differences in pain and quality of life in the patients with spinal fusion for OVFs.

This study has several limitations. First, the multicentre retrospective design of the study meant that we could not evaluate the duration of drug administration in all cases. Although TP should be administered

for 2 years in Japan, information on the exact treatment duration could not be obtained. Therefore, it is possible that there were patients in the study who had received TP for a shorter duration. Second, we could not investigate the preoperative use of osteoporosis medications. However, the BMD was similar between the two treatment groups, suggesting that any difference in the effect of drugs administered preoperatively was negligible. Further studies with more appropriate study designs are needed.

## Conclusions

In this study, the effect of postoperative TP on the overall mechanical complication rate was more favourable than that of a BP regardless of whether the osteoporosis is primary or glucocorticoid-induced. The incidence of pseudoarthrosis was significantly higher in patients with GIOP. The use of TP reduced the rate of pseudoarthrosis in GIOP patients.

## Abbreviations

BMD, bone mineral density; BP, bisphosphonate; GIOP, glucocorticoid-induced osteoporosis; JOA, Japanese Orthopaedic Association; OVF, osteoporotic vertebral fracture; TP, teriparatide; VAS, visual analogue scale; YAM, Young Adult Mean

## Declarations

### Ethics approval and consent to participate

This study was approved by the ethics committee of all participating institutions. The need for informed consent was waived by the above ethics committees because the retrospective cohort study involved existing data and records at the time of investigation, and did not retain personal identifiers in the collected information.

Ethics committee, Niigata University School of Medicine (approval number 2015-1385)

Ethics committee, Osaka University School of Medicine (approval number 11360-3)

Ethics committee, Tokyo Medical University (approval number 2605)

Ethics committee, Osaka City University School of Medicine (approval number 3170)

Ethics committee, Nagasaki University School of Medicine (approval number 17032715)

Ethics committee, Tokyo Medical and Dental University (approval number M2016-055)

Ethics committee, Kyushu University School of Medicine (approval number 28-359)

Ethics committee, Jichi Medical University (approval number A13-82)

Ethics committee, Kitasato University School of Medicine (approval number B16-34)

Ethics committee, Osaka Medical College (approval number 2169)

Ethics committee, Tokai University School of Medicine (approval number 16R-033)

Ethics committee, Shinshu University School of Medicine (approval number 3456)

Ethics committee, Chiba University School of Medicine (approval number 2481)

Ethics committee, Nagoya University School of Medicine (approval number 2016-0177)

Ethics committee, Kochi University School of Medicine (approval number 2016-116)

Ethics committee, Kanazawa University School of Medicine (approval number 2015-075)

Ethics committee, University of Toyama School of Medicine (approval number 21-22)

Ethics committee, Akita University School of Medicine (approval number 1879)

Ethics committee, Kobe University School of Medicine (approval number 160004)

Ethics committee, Nihon University Itabashi Hospital (approval number RK-160913-21)

Ethics committee, Hokkaido University School of Medicine (approval number 015-0396)

Ethics committee, Iwate Medical University (approval number H28-88)

Ethics committee, University of Tsukuba School of Medicine (approval number H27-133)

Ethics committee, Hiroshima University School of Medicine (approval number Epi-139)

Ethics committee, Keio University School of Medicine (approval number 20110141)

### **Consent for publication**

Not applicable

### **Availability of data and materials**

The datasets generated during and/or analysed during this study are available from the corresponding author on reasonable request.

### **Competing interests**

The authors declare that they have no competing interests.

### **Funding**

Not applicable.

## Authors' contributions

AK1: study design, analyses and interpretation of data, draft of manuscript with tables and figures; TY: substantial contributions to conception and critical revision for important intellectual content; TH1, SU, TK, YM, HT, AT, KH, KK2, AK2, GI, AN, DS, SI1, SO1, TF, SI2, KK4, HM, SS, MH, KK5, YA, MO2, MT, HE, TA, KN, KW2, NH, KI, and TH2: substantial contributions to study design and data acquisition; KK1, MO1, YS, TY, HF, YN, HS, HN, KT, SY, SA, NY, HO, TD, HI, MM, WS, TN, MS, TF, SO2, KA, KK3, KY, TY, AI, TT, SS, NI, EO, HF, SU, YS, and KN: data acquisition. All authors read and approved the final manuscript.

## Acknowledgments

Not applicable.

## References

1. Tsuda T. Epidemiology of fragility fractures and fall prevention in the elderly: a systematic review of the literature. *Curr Orthop Pract*. 2017;28(6):580-5.
2. Kato T, Inose H, Ichimura S, Tokuhashi Y, Nakamura H, Hoshino M, et al. Comparison of rigid and soft-brace treatments for acute osteoporotic vertebral compression fracture: a prospective, randomized, multicenter study. *J Clin Med*. 2019;8(2).
3. Hosogane N, Nojiri K, Suzuki S, Funao H, Okada E, Isogai N, et al. Surgical treatment of osteoporotic vertebral fracture with neurological deficit - a nationwide multicenter study in Japan. *Spine Surg Relat Res*. 2019;3(4):361-7.
4. Zhong W, Liang X, Luo X, Quan Z. Vertebroplasty and vertebroplasty in combination with intermediate bilateral pedicle screw fixation for OF4 in osteoporotic vertebral compression fractures: a retrospective single-centre cohort study. *BMC Surg*. 2019;19(1):178.
5. Watanabe K, Katsumi K, Ohashi M, Shibuya Y, Izumi T, Hirano T, et al. Surgical outcomes of spinal fusion for osteoporotic thoracolumbar vertebral fractures in patients with Parkinson's disease: what is the impact of Parkinson's disease on surgical outcome? *BMC Musculoskelet Disord*. 2019;20(1):103.
6. Byun JH, Jang S, Lee S, Park S, Yoon HK, Yoon BH, et al. The efficacy of bisphosphonates for prevention of osteoporotic fracture: an update meta-analysis. *J Bone Metab*. 2017;24(1):37-49.
7. Liu CL, Lee HC, Chen CC, Cho DY. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. *Clin Invest Med*. 2017;40(3):E146-E157.
8. Murphy DR, Smolen LJ, Klein TM, Klein RW. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden. *BMC Musculoskelet Disord*. 2012;13:213.

9. Yamazaki T, Takahashi K, Bessho K. Recent clinical evidence in bisphosphonate-related osteomyelitis of the jaw: focus on risk, prevention and treatment. *Rev Recent Clin Trials*. 2014;9(1):37-52.
10. Iwata K, Mashiba T. Pathogenesis of atypical femoral fracture. *Clin Calcium*. 2016;26(1):73-9.
11. Oh Y, Wakabayashi Y, Kurosa Y, Fujita K, Okawa A. Potential pathogenic mechanism for stress fractures of the bowed femoral shaft in the elderly: mechanical analysis by the CT-based finite element method. *Injury*. 2014;45(11):1764-71.
12. Jakob F, Oertel H, Langdahl B, Ljunggren O, Barrett A, Karras D, et al. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. *Eur J Endocrinol*. 2012;166(1):87-97.
13. Iwata A, Kanayama M, Oha F, Hashimoto T, Iwasaki N. Effect of teriparatide (rh-PTH 1-34) versus bisphosphonate on the healing of osteoporotic vertebral compression fracture: a retrospective comparative study. *BMC Musculoskelet Disord*. 2017;18(1):148.
14. Langdahl BL, Ljunggren Ö, Benhamou CL, Marin F, Kapetanios G, Kocjan T, et al. Fracture rate, quality of life and back pain in patients with osteoporosis treated with teriparatide: 24-month results from the Extended Forsteo Observational Study (ExFOS). *Calcif Tissue Int*. 2016;99(3):259-71.
15. Seki S, Hirano N, Kawaguchi Y, Nakano M, Yasuda T, Suzuki K, et al. Teriparatide versus low-dose bisphosphonates before and after surgery for adult spinal deformity in female Japanese patients with osteoporosis. *Eur Spine J*. 2017;26(8):2121-7.
16. Maruo K, Tachibana T, Arizumi F, Kusuyama K, Kishima K, Yoshiya S. Effect of teriparatide on subsequent vertebral fractures after instrumented fusion surgery for osteoporotic vertebral fractures with neurological deficits. *Asian Spine J*. 2019;13(2):283-9.
17. Kim JW, Park SW, Kim YB, Ko MJ. The effect of postoperative use of teriparatide reducing screw loosening in osteoporotic patients. *J Korean Neurosurg Soc*. 2018;61(4):494-502.
18. Chen YC, Lin WC. Can anti-osteoporotic therapy reduce adjacent fracture in magnetic resonance imaging-proven acute osteoporotic vertebral fractures? *BMC Musculoskelet Disord*. 2016;17:151.
19. Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, et al. Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. *Spine (Phila Pa 1976)*. 2013;38(8):E487-92.
20. Ohtori S, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kuniyoshi K, et al. More than 6 months of teriparatide treatment was more effective for bone union than shorter treatment following lumbar posterolateral fusion surgery. *Asian Spine J*. 2015;9(4):573-80.
21. Watanabe K, Katsumi K, Ohashi M, Shibuya Y, Hirano T, Endo N, et al. Surgical outcomes of spinal fusion for osteoporotic vertebral fracture in the thoracolumbar spine: comprehensive evaluations of 5 typical surgical fusion techniques. *J Orthop Sci*. 2019;24(6):1020-6.
22. Hirabayashi K, Miyakawa J, Satomi K, Maruyama T, Wakano K. Operative results and postoperative progression of ossification among patients with ossification of cervical posterior longitudinal

- ligament. *Spine (Phila Pa 1976)*. 1981;6(4):354-64.
23. Compston J. Glucocorticoid-induced osteoporosis: an update. *Endocrine*. 2018;61(1):7-16.
24. Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. *Osteoporos Int*. 2019;30(6):1145-56.
25. Saito M, Marumo K. Determinants of bone quality and strength independent of bone remodeling. *Clin Calcium*. 2016;26(1):29-41.
26. Waters RV, Gamradt SC, Asnis P, Vickery BH, Avnur Z, Hill E, et al. Systemic corticosteroids inhibit bone healing in a rabbit ulnar osteotomy model. *Acta Orthop Scand*. 2000;71(3):316-21.
27. Sawin PD, Dickman CA, Crawford NR, Melton MS, Bichard WD, Sonntag VK. The effects of dexamethasone on bone fusion in an experimental model of posterolateral lumbar spinal arthrodesis. *J Neurosurg*. 2001;94(1 Suppl):76-81.
28. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum*. 2009;60(11):3346-55.